Genotypic and phenotypic M. tuberculosis resistance: Guiding clinicians to prescribe the correct regimens

European Respiratory Journal

Volumn 50, Issue 6, 2017, Pages

  Cabibbe, Andrea Maurizio ^a   Sotgiu, Giovanni ^b   Izco, Santiago ^c,d   Migliori, Giovanni Battista ^e  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d Manhiça Health Research Center   (Mozambique)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; DRUG USE; EIS GENE; EMBB GENE; ETHA GENE; FURA GENE; GENE MUTATION; GENOTYPE; GIDB GENE; GYRA GENE; GYRB GENE; HUMAN; INHA GENE; KATG GENE; MABA GENE; MOLECULAR DIAGNOSIS; MSHA GENE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RPOB GENE; RPSL GENE; RRS GENE; TAP GENE; TLYA GENE; WHIB7 GENE; DRUG EFFECT; MICROBIAL SENSITIVITY TEST; MUTATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; TUBERCULOSIS;

EID: 85043474322     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02292-2017     Document Type: Review

References (27)

1. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
2. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
3. Sotgiu G, Pontali E, Centis R, et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther 2015; 13: 305-315.
4. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and MDR-TB: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402.
5. Pontali E, D'Ambrosio L, Centis R, et al. Multidrug-resistance tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. Eur Respir J 2017; 49: 1700146.
6. Borisov SE, Dheda K, Enwerem M. Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study. Eur Respir J 2017; 49: 1700387.
7. Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J 2017; 50: 1701462.
8. Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 2015; 45: 25-29.
9. Dalcolmo M, Gayoso R, Sotgiu G, et al. Effectiveness and safety of clofazimine within a standard multidrug-resistant tuberculosis regimen in Brazil: first nation-wide report on over 2,500 cases. Eur Respir J 2017; 49: 1602445.
10. Tiberi S, Payen MC, Sotgiu G, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 1235-1243.
11. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR-and XDR-TB. Eur Respir J 2016; 47: 1758-1766.
12. Falzon D, Schunemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
13. Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug-resistance in Mycobacterium tuberculosis. Eur Respir J 2017; 50: 1701354.
14. Gilpin C, Korobitsyn A, Weyer K. Current tools available for the diagnosis of drug-resistant tuberculosis. Ther Adv Infectious Dis 2016; 3: 145-151.
15. Rieder HL, Van Deun A. Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2017; 21: 123-124.
16. Jacobson K R, Theron D, Victor T C, et al. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 2011; 53: 369-372.
17. Cambau E, Viveiros M, Machado D, et al. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J Antimicrob Chemother 2015; 70: 686-696.
18. van Ingen J, Aarnoutse R, de Vries G, et al. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis 2011; 15: 990-992.
19. ElMaraachli W, Slater M, Berrada ZL, et al. Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations. Int J Tuberc Lung Dis 2015; 19: 1222-1226.
20. Jamieson FB, Guthrie JL, Neemuchwala A, et al. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol 2014; 52: 2157-2162.
21. Schön T, Juréen P, Chryssanthou E, et al. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? J Antimicrob Chemother 2013; 68: 2074-2077.
22. Kambli P, Ajbani K, Sadani M, et al. Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. Tuberculosis (Edinb) 2015; 95: 137-141.
23. Willby M, Sikes RD, Malik S, et al. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 5427-5434.
24. Chien J-Y, Chien S-T, Chiu W-Y, et al. Moxifloxacin improves treatment outcomes in patients with ofloxacin-resistant multidrug resistant tuberculosis. Antimicrob Agents Chemother 2016; 60: 4708-4716.
25. Chien J-Y, Chiu W-Y, Chien S-T, et al. Mutations in gyrA and gyrB among fluoroquinolone-and multidrug-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2016; 60: 2090-2096.
26. Xu Y, Wu J, Liao S, et al. Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. Ann Clin Microbiol Antimicrob 2017; 16: 67.
27. The 48th Union World Conference on Lung Health, Guadalajara, Mexico. STREAM clinical trial results provide vital insight into nine-month treatment regimen for multidrug-resistant tuberculosis. http://guadalajara.worldlunghealth.org/media/conference-news/updates/stream-clinical-trial-results-provide-vital-insight-into-ninemonth-treatment-regimen-for-multidrug-resistant-tuberculosis Date last accessed: November 5, 2017.